Maatman T J, Gupta M K, Montie J E
J Urol. 1984 Jul;132(1):58-60. doi: 10.1016/s0022-5347(17)49463-8.
Serial serum prostatic acid phosphatase levels were obtained every 4 hours during a 48-hour interval from 10 men with stage D adenocarcinoma of the prostate. No therapeutic or diagnostic manipulations occurred during sample procurement, so that the amount of fluctuation of serum prostatic acid phosphatase levels that can be expected in these patients could be determined. The coefficient of variation for each man ranged from 16.67 to 43.68 per cent, which was significantly higher than the expected 8 per cent coefficient of variation determined with a control sample. The maximum percentage variations above and below the mean were 79 and 50 per cent, respectively. The average percentage variation in all patients was within 50 per cent greater than and 50 per cent less than the mean value of prostatic acid phosphatase. Thus, the usefulness of serum acid phosphatase by radioimmunoassay as a clinical tumor marker is limited by the number of serial assays needed to establish a mean. Based on these findings, certain guidelines are suggested.
在48小时内，每隔4小时对10名患有D期前列腺腺癌的男性进行血清前列腺酸性磷酸酶水平的连续检测。在采集样本期间未进行任何治疗或诊断操作，从而能够确定这些患者血清前列腺酸性磷酸酶水平的波动幅度。每名男性的变异系数在16.67%至43.68%之间，显著高于对照样本预期的8%的变异系数。高于和低于平均值的最大百分比变化分别为79%和50%。所有患者的平均百分比变化在高于前列腺酸性磷酸酶平均值50%和低于平均值50%的范围内。因此，通过放射免疫测定法检测血清酸性磷酸酶作为临床肿瘤标志物的有效性受到建立平均值所需的连续检测次数的限制。基于这些发现，提出了某些指导原则。
